About Rolex Rings Limited –
Incorporated in 2003, Rolex Rings is among the top five forging companies in India. The company manufactures hot rolled forged & machine bearing rings and automotive components. The company supplies its products in India as well as 17 different countries, which include France, Italy, Germany, Thailand, Czech Republic and USA. Nearly 55 percent of revenue comes from outside India. It has 3 manufacturing plants in Rajkot with 22 forging lines.
IPO Details –
IPO Date – 28 July to 30 July
Price band – 880 to 900rs
Lot size – 16 Shares
Proposed Listing Date – 9th august
Issue Size – 731Cr (Fresh issue – 56cr and OFS – 675cr)
Post Issue promoter Holding – 57.64%
Negative point of the company –
The revenues of the company has declined on 4 year basis.
High dependence on performance of automotive sector.
In 2013 company defaulted in payment of certain loans, and approached CDR cell for debt restructuring.
Positive point of the company –
Company has been able to significantly improve its financial profile with the debt-equity ratio improving from 1.79 times as at March 2019 to 0.70 times as of March 2021.
It has credit rating of BB with stable outlook by CARE.
Good net cash flow from operating activities.
The company earned a profit of Rs 86.95 crore in FY21 on revenues of Rs 616.33 crore and profit of Rs 52.94 crore on revenues of Rs 665.99 crore in FY20.
EPS of the company is approx 25rs. And it is available at a PE of 42 times, which is good when we compare it with industry PE of 77.
Keeping above things in mind, one may subscribe in this IPO for listing gains.
Disclaimer – Views shared is only for educational purpose. I am not a SEBI registered advisor. Please consult your financial advisor before making any investment.
If you liked this post, then consider subscribing to our YouTube channel for more such updates – https://www.youtube.com/c/equityways
GLENMARK LIFE SCIENCES LTD –
Incorporated as Zorg Laboratories Private Limited in 2011, it was acquired by Glenmark Pharmaceuticals Limited in 2018. It is one of the leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) is aslo providing contract development and manufacturing operations (CDMO) services to many multinational and specialty pharmaceutical companies. 90% of the revenue comes from API business. Geographically, 56% revenue comes from India and remaining 44% from foreign countries. Company has 4 manufacturing units (2 in Gujarat and 2 in Maharashtra) and 3 R&D facilities. Company exports its products to Europe, Latin America, North America, Japan, and the rest of the world.
Issue Details –
Issue Date – 27 July to 29 July
Price Band – 695 to 720rs
Lot size – 20
Issue Size – 1514cr (fresh issue – 1060cr and OFS – 454cr)
Post-Issue Market Cap – 8822 cr
Retail quota – 35%
Proposed Listing Date – 6 August
Post issue promoter holding – 83%
Negative points –
35% of its raw material comes from china.
Revenue concentration – 90% of the revenue comes from API business.
Post issue debt to equity ratio – 0.5 (which is manageable)
Positive points of the company –
IPO is priced at 25 times PE. Whereas its main competitors Divis Lab, Laurus Labs and Shilpa Medicare are trading at a P/E of 64X, 36X and 36.5X respectively.
The company has registered a 2-Yr CAGR of 45.8% and 34.1% in its sales and PAT respectively.
Strong parentage of Glenmark Pharmaceuticals.
Keeping above things in mind, one may subscribe in this IPO for listing gains.
Disclaimer – Views shared is only for educational purpose, so that you all can take a better informed decision. I am not a SEBI registered advisor. Please consult your financial advisor before making any investment.
If you liked this post, then consider subscribing to our YouTube channel for more such updates – https://www.youtube.com/c/equityways
NSE or National Stock Exchange is open on the weekdays from Monday to Friday and is closed on Saturday and Sunday, except any special trading sessions are announced. Here’s the complete list of NSE Holidays 2021. Save this post for future reference.
My views on Mazagon Dock Shipbuilders Limited IPO –
IPO Price – ₹135 to ₹145 per equity share
Last date – Oct 1, 2020
Proposed listing date – Oct 12, 2020
Minimum bid quantity – 103 shares
Minimum bid amount – ₹14935
Incorporated in 1934, Mazagon Dock Shipbuilders Ltd (Miniratna category-1′ status company) is the India’s leading defence public sector undertaking shipyard under the Ministry of Defence. Mazagon Dock is primarily engaged in constructing and repairing warships and submarines.
The major customers for the shipyard include Indian Navy and Coast Guard. The company is India’s only shipyard to have built destroyers and conventional submarines for the Indian Navy.
MDS’s shipbuilding and submarine contracts have a long gestation period and its revenues under these contracts are dependent on the achievement of certain milestones. In order to diversify its revenue streams, the company intend to increase its ship repair activities in the future as such activities are for a shorter period of time and result in the early booking of revenues. The company has undertaken ship repairs in the past for its clients in the defence and commercial sectors. This will help generate more revenues, increase the company’s client base and reduce its dependency on the MoD for future orders.
The company is a consistent dividend paying company with an average payout ratio of over 36.8% over FY17-20. Company has very strong order book. Profit after tax has declined on annual basis. At higher price band, company is valued at PE of 6.8, And industry PE is near 8.
My final view on IPO –
IPO looks good to me. But chances of allotment are very less. Lucky ones, who’ll get allotment can expect 50% or more profit on listing day. Company looks good even for long term holding.